Sign up
Tech Capital
EPIC: INS
Market: AIM
52-week High/Low: 333.92p / 140.00p
Sector: Software & Computer Services
Market Cap: 47.74M

We help our over 500 international clients efficiently access, capture, analyze, report and submit high quality regulatory data, while maintaining compliance for their products around the world. This is combined with our unique ability to generate new knowledge through the extraction and harmonization of public and proprietary sources of actionable scientific information.

Instem Plc

www.instem-lss.com

Interactive graph

col 3
col 4
col 5
col 6

Big picture - Why invest in Instem Plc

Instem Plc Snapshot

For the more than 500 clients around the world, we are supplying breakthrough technology and services that help them efficiently access, capture, manage and enrich a wide array of data while generating new insight to advance their mission.

Instem clients experience measurable benefits such as:

Greater confidence in the safety and efficacy of their product portfolio
Shorter R&D cycles with reduced costs
Better management controls
Increased regulatory compliance
More effective resource utilization with greater staff satisfaction
Happier and healthier clinical subjects
Enhanced care and reduction of animal usage
As a result, we enjoy a greater than 98% client retention rate – a statistic that we believe is the true measure of our success. More than just another IT vendor, as a solutions provider we act as a client’s strategic partner helping to optimize their processes, increase the satisfaction of their sponsors and partners while helping them become more competitive in their local, regional and global marketplaces.

Our leadership position is built on a solid history of inspired, focused innovation and an unrelenting determination to deliver exceptional value and return to our customers, partners, staff and investors.

In a highly fragmented life science IT marketplace, Instem is one of very few organizations that have clearly developed the financial strength necessary to maintain global leadership with established products, while introducing new regulatory compliant solutions that are delivering the step change in productivity that clients are aggressively pursuing.

Every product we develop, every service we provide – they are all part of a solution our clients are looking for to advance their life-improving missions.

Innovation is at the heart of every Instem Product

Government research

Our Products
Provantis® Preclinical
Submit™ SEND
ALPHADAS® early phase clinical
ACIS™ Animal Care Information System
Logbook™ ELN
TRP™ resource planning
Comet Assay IV™
Cyto Study Manager
Ames Study Manager™
Sorcerer Colony Counter™
NOTOCORD-hem™ Safety Pharmacology Solution
Samarind RMS - NEW!
SEND Explorer® - NEW!
SENDTrial - NEW!
SRS™ Bioinformatics


Our Services
Instem Cloud
SEND Data Conversion
KnowledgeScan
SENDReady™ Consulting
Solution Deployment
Validation
Data Management
Regulatory Information Management

 

For more information please click here 

Phil Reason*
Chief Executive Officer

Phil has been leading Instem as CEO since 1995, working closely with the Instem Board, investors, management, clients, partners and staff to grow the business from a single product line with fifteen clients to serving hundreds of customers as the global market leader across a wide area of life sciences R&D.  Passionate about Instem’s ability to support clients in introducing transformational approaches for life changing therapies, Phil has been a vocal advocate of long-term partnerships, innovative organic growth, geographic expansion and the acquisitive consolidation of the fragmented IT supplier community. Under Phil’s leadership Instem has completed the strategic acquisition of 6 companies, has opened new offices in the US, UK, China, and India and has completed a UK-based IPO in 2010.

Gordon Baxter BSc, PhD
Chief Scientific Officer

A pharmacologist, Gordon has held several senior discovery positions in major pharmaceutical companies and was a founding entrepreneur of the CRO, Pharmagene plc. and held positions of Chief Scientific Officer and Chief Operating Officer. He was also a founder of the UK-based healthcare intelligence company, BioWisdom Ltd which was acquired by Instem in 2011. He has a track record of innovation in drug discovery and has contributed to the development of several marketed drugs. He is an advocate of Translational Informatics; using data gathered from research, development and medical practice to generate new therapeutic insights. Gordon is on the Board of the R&D information technology group, the Pistoia Alliance.

Vince D’Angelo
Vice President, Global Quality Assurance

Vince is responsible for Instem’s ISO9001 certification and oversees quality at all Instem office locations around the world for all product lines.  Vince has been with Instem since 1988 having had roles in software development and computer systems validation. He has developed processes that have successfully passed inspection by regulatory bodies and has been at the forefront in the use of automated test tools to provide regression testing and qualification evidence.
Vince is a Fellow of the Research Quality Association (RQA), an active member of the Society of Quality Assurance (SQA) and regularly gives presentations at their annual conferences and is the past Chair of the SQA Computer Validation, Information technology, Compliance (CVIC) specialty section which currently has members from many of today’s leading Pharmaceutical companies and contract research organizations.

Adrian Gare
Vice President, Corporate Development

Supporting Instem’s strategy to identify suitable acquisition and partnership opportunities to help consolidate and empower the R&D IT community, Adrian is responsible for sourcing and transacting key strategic projects around the world. Adrian’s accomplishments include Instem’s acquisitions of BioWisdom, Logos Technologies and Perceptive Instruments and he is involved in collaborative licensing agreements and joint ventures. Adrian is a qualified chartered accountant with over 15 years of experience in corporate finance and M&A activities and has a proven track record of success with a Top-10 firm of accountants.

Nigel Goldsmith*
Chief Financial Officer

Nigel joined Instem in November of 2011 and possesses a wealth of experience in senior financial roles at both public and private companies within the life sciences industry. Prior to Instem, Nigel was Finance Director for 3 years at the AIM listed, pharmaceutical and medical devices company, IS Pharma plc. He also held the position of CFO for 7 years at Almedica International Inc., a privately held supplier of clinical trial materials to the global pharmaceutical and biotech markets and 2 years as European Controller for the sales and marketing division of laboratory equipment manufacturer, Life Sciences International plc. Prior to entering industry, Nigel spent over 9 years at KPMG and is a qualified Chartered Accountant.

*Board member

Board of Directors

Gregor Grant
Executive Vice President, Preclinical Solutions

Gregor is an experienced leader with a proven track record of success in developing customer relationships and delivering IT solutions for the Life Sciences Industry. Gregor is passionate about ensuring the exceptional client experience and his team provides development, deployment and support services to Instem’s Preclinical Solutions clients around the world, including products from the acquisition of Perceptive Instruments in 2013. Gregor joined Instem through an acquisition of Apoloco in 1996, a smaller competitor specializing in pathology solutions.  For over 20 years Gregor has been instrumental in helping create both a successful software product, and building a reputation for high quality and service within a passionate and demanding user community.  

Mike Harwood
Executive Vice President, Regulatory eStudy Solutions

Mike joined Instem in 1999 through the acquisition of Fraser Williams Data Systems where he was a Director overseeing Client Services.  While most of Mike’s more recent experience has been in the deployment of regulatory preclinical solutions, since 1977 he has worked on applications across the R&D continuum from early stage chemical databases to late stage clinical trials systems. Mike joined the SEND standard development team back in 2003 providing key input and was pivotal in bringing the first commercial SEND software solution to market in 2005. Mike now leads a team of industry experts supporting the most comprehensive and widely deployed set of tools and services for SEND in today’s global marketplace.

Hilary McCarthy
Vice President, Global Human Resources

Hilary joined Instem in February 2013 and is responsible for setting HR strategy, providing HR management, improving employee engagement and contributing to organizational development. Hilary has over 20 years of senior management and leadership experience across international IT, health and education sectors and along with her deep human resource expertise is highly commercially-focused, with strong proficiencies in leadership training and business development.
As Instem continues to invest heavily in its staff and related processes amidst both organic and acquisitive growth, Hilary and her team helps attract subject matter experts in all of our marketplaces while ensuring Instem remains to be one of the best places to work.

Gary Mitchell
Vice President, Global Marketing

Gary leads an international team responsible for the development of programs that help generate demand for Instem’s software solutions and services. He helps create and carry out our strategic growth plans by positioning and promoting Instem as the global leader of technologies that empower mission critical R&D programs to introduce better drugs, therapies & products more quickly. For more than 20 years Gary has held key management positions where he has developed high-impact B2B marketing programs & processes and is well versed in strategic market planning, new product branding and launches. Prior to joining Instem in May of 2004, Gary was a Senior Marketing Specialist with Dun & Bradstreet focused on creating and executing business development and go-to-market programs for its B2B Sales & Marketing products.

Shares in Issue
Number of securities in issue
The Company’s issued share capital consists of ordinary shares with a nominal value of 10p pence each (“Ordinary Shares”), each share having equal voting rights.

The Company does not hold any Ordinary Shares in treasury and therefore the total number of Ordinary Shares with voting rights is 15,912,431. (Last updated: 14 March 2018)

Director Shareholdings

Director Name Amount % Holding
David Sherwin 1,380,066 8.7%
David Gare 1,258,427 7.9%
Phil Reason 665,287 4.2%
Mike McGoun 36,786 0.2%

 

 

Instem plc Registered Office

Diamond Way
Stone Business Park
Stone
Staffordshire
ST15 0SD
United Kingdom

Registered in England & Wales No. 07148099
Country of incorporation: England

 

UK Headquarters

Tel: +44 (0) 1785 825600

 

Financial Advisor, NOMAD and Broker N+1 Singer
One Bartholomew Lane
London
EC2N 2AX

Lawyers Squire Patton Boggs (UK) LLP
Trinity Court
16 John Dalton Street
Manchester
M60 8HS

Reporting Accountants RSM Corporate Finance LLP
3 Hardman Street
Manchester
M3 3HF

Auditors RSM UK Audit LLP
3 Hardman Street
Manchester
M3 3HF

Registrars Computershare Investor Services PLC
Bridgwater Road
Bristol
BS13 8AE

Financial PR Walbrook PR Limited
4 Lombard Street
London
EC3V 9HD

Banker National Westminster Bank Plc
1 Spinningfields Square
Deansgate
Manchester
M3 3AP

View full INS profile View Profile
View All

Market Reports Including INS

VIEW ALL

Executive video interviews

VIEW ALL VIDEOS

© tech Capital 2018

Tech Capital, a subsidiary of Proactive Investors, acts as the vanguard for listed tech companies to interact with institutional and highly capitalised investors.
Headquartered in London, Tech Capital is led by a team of Europe's leading analysts and journalists, publishing daily content, covering all key movements in the Technology market.